Clinical trials: Diabetes, Type II
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of…
- Trial name
- NCT02229227
- Testing
- Albiglutide, Insulin Glargine and Insulin Lispro
- Where
- 157 sites in United States, Brazil and 12 more
- Volunteers
- 814 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT01022112
- Testing
- TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle
- Where
- 6 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin…
- Trial name
- NCT01462266
- Testing
- Sitagliptin, Insulin Glargine, Metformin
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
This study aims to assess how glimepiride affects the recovery from hypoglycemia in participants with type 2 diabetes mellitus. The primary objective is to estimate the time taken by participants to recover from hypoglycemia to…
- Trial name
- NCT01614769
- Testing
- Glimepiride 2 mg, Glimepiride 4 mg, Hypoglycemic Clamp
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2 With Hyperglycemia
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
- Trial name
- NCT02303405
- Testing
- Hydroxychloroquine, Pioglitazone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetes Mellitus, Type 2
Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
The purpose of the study was to evaluate the efficacy and safety of LMF237 50/250 mg and 50/500 mg bid in Japanese patients with T2DM inadequately controlled with vildagliptin monotherapy.
- Trial name
- CLMF237A1303 (NCT01811485)
- Testing
- LMF237 50/250 mg, LMF237 50/500 mg
- Where
- 30 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly.
- Trial name
- FIGARO-BM (NCT05013008)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 115 sites in United States, Australia and 19 more
- Volunteers
- 951 people
- Sponsor
- Bayer
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
A Study of LY3025876 in Participants With Diabetes
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01870297
- Testing
- LY3025876, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
The purpose of this study is to determine whether dapagliflozin is effective in the treatment of type 2 diabetes in subjects with poor blood sugar control and moderate renal impairment
- Trial name
- NCT00663260
- Testing
- Dapagliflozin
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 631 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01849289)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- 81 sites in United States, Brazil and 5 more
- Volunteers
- 833 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.
- Trial name
- JAS (NCT01195090)
- Testing
- Sitagliptin, pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Sung-Chen Liu
Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir…
- Trial name
- NCT00998335
- Testing
- Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Type 2 Diabetes
Vitamin D Supplementation on Cardiovascular Risk Factors
The purpose of the present pilot study is to determine the effect of vitamin D supplementation (4000 IU or 6000 IU once daily for 6 months) on reducing heart disease risk and in improving blood glucose control in type 2 Diabetes…
- Trial name
- NCT01412710
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Florida International University
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.